Indolent infections in patients with hematologic malignancy: A single-center experience screening for tuberculosis and strongyloidiasis prior to cytotoxic therapy in Boston
Individuals with hematologic malignancy have increased risk of latent tuberculosis infection (LTBI) reactivation and Strongyloides stercoralis (SS) dissemination. However, screening prior to chemotherapy or corticosteroids is not routine. We conducted a LTBI and SS screening intervention amongst pat...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Leukemia Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048924000797 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846139902833459200 |
|---|---|
| author | K.A. Reifler T. Francoeur Smith G. Bodanapu M. Fagan D.L. Bourque J.M. Sloan |
| author_facet | K.A. Reifler T. Francoeur Smith G. Bodanapu M. Fagan D.L. Bourque J.M. Sloan |
| author_sort | K.A. Reifler |
| collection | DOAJ |
| description | Individuals with hematologic malignancy have increased risk of latent tuberculosis infection (LTBI) reactivation and Strongyloides stercoralis (SS) dissemination. However, screening prior to chemotherapy or corticosteroids is not routine. We conducted a LTBI and SS screening intervention amongst patients with hematologic malignancies. Over one-third immigrated from countries with high TB incidence and SS prevalence, and some had additional risk factors (HIV, HTLV-1, eosinophilia). The intervention increased screening rates but universal screening was not achieved. Screening positivity was similar pre- and post-intervention. We demonstrate a population with increased indolent infection reactivation risk. Specific infectious screening guidelines are needed to prevent significant morbidity. |
| format | Article |
| id | doaj-art-9e3a4266363a4731bc7c2f7ed8e319f0 |
| institution | Kabale University |
| issn | 2213-0489 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Leukemia Research Reports |
| spelling | doaj-art-9e3a4266363a4731bc7c2f7ed8e319f02024-12-06T05:13:29ZengElsevierLeukemia Research Reports2213-04892024-01-0122100489Indolent infections in patients with hematologic malignancy: A single-center experience screening for tuberculosis and strongyloidiasis prior to cytotoxic therapy in BostonK.A. Reifler0T. Francoeur Smith1G. Bodanapu2M. Fagan3D.L. Bourque4J.M. Sloan5Section of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA; Corresponding author at: Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Boston, MA 02118, USA.Department of Internal Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USABoston University Chobanian & Avedisian School of Medicine, Boston, MA, USASection of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USASection of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USASection of Hematology/Oncology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USAIndividuals with hematologic malignancy have increased risk of latent tuberculosis infection (LTBI) reactivation and Strongyloides stercoralis (SS) dissemination. However, screening prior to chemotherapy or corticosteroids is not routine. We conducted a LTBI and SS screening intervention amongst patients with hematologic malignancies. Over one-third immigrated from countries with high TB incidence and SS prevalence, and some had additional risk factors (HIV, HTLV-1, eosinophilia). The intervention increased screening rates but universal screening was not achieved. Screening positivity was similar pre- and post-intervention. We demonstrate a population with increased indolent infection reactivation risk. Specific infectious screening guidelines are needed to prevent significant morbidity.http://www.sciencedirect.com/science/article/pii/S2213048924000797Disseminated strongyloidiasisTuberculosis reactivationInfectious screeningPre-immunosuppression screeningCorticosteroids risk |
| spellingShingle | K.A. Reifler T. Francoeur Smith G. Bodanapu M. Fagan D.L. Bourque J.M. Sloan Indolent infections in patients with hematologic malignancy: A single-center experience screening for tuberculosis and strongyloidiasis prior to cytotoxic therapy in Boston Leukemia Research Reports Disseminated strongyloidiasis Tuberculosis reactivation Infectious screening Pre-immunosuppression screening Corticosteroids risk |
| title | Indolent infections in patients with hematologic malignancy: A single-center experience screening for tuberculosis and strongyloidiasis prior to cytotoxic therapy in Boston |
| title_full | Indolent infections in patients with hematologic malignancy: A single-center experience screening for tuberculosis and strongyloidiasis prior to cytotoxic therapy in Boston |
| title_fullStr | Indolent infections in patients with hematologic malignancy: A single-center experience screening for tuberculosis and strongyloidiasis prior to cytotoxic therapy in Boston |
| title_full_unstemmed | Indolent infections in patients with hematologic malignancy: A single-center experience screening for tuberculosis and strongyloidiasis prior to cytotoxic therapy in Boston |
| title_short | Indolent infections in patients with hematologic malignancy: A single-center experience screening for tuberculosis and strongyloidiasis prior to cytotoxic therapy in Boston |
| title_sort | indolent infections in patients with hematologic malignancy a single center experience screening for tuberculosis and strongyloidiasis prior to cytotoxic therapy in boston |
| topic | Disseminated strongyloidiasis Tuberculosis reactivation Infectious screening Pre-immunosuppression screening Corticosteroids risk |
| url | http://www.sciencedirect.com/science/article/pii/S2213048924000797 |
| work_keys_str_mv | AT kareifler indolentinfectionsinpatientswithhematologicmalignancyasinglecenterexperiencescreeningfortuberculosisandstrongyloidiasispriortocytotoxictherapyinboston AT tfrancoeursmith indolentinfectionsinpatientswithhematologicmalignancyasinglecenterexperiencescreeningfortuberculosisandstrongyloidiasispriortocytotoxictherapyinboston AT gbodanapu indolentinfectionsinpatientswithhematologicmalignancyasinglecenterexperiencescreeningfortuberculosisandstrongyloidiasispriortocytotoxictherapyinboston AT mfagan indolentinfectionsinpatientswithhematologicmalignancyasinglecenterexperiencescreeningfortuberculosisandstrongyloidiasispriortocytotoxictherapyinboston AT dlbourque indolentinfectionsinpatientswithhematologicmalignancyasinglecenterexperiencescreeningfortuberculosisandstrongyloidiasispriortocytotoxictherapyinboston AT jmsloan indolentinfectionsinpatientswithhematologicmalignancyasinglecenterexperiencescreeningfortuberculosisandstrongyloidiasispriortocytotoxictherapyinboston |